Company Summary - ReNeuron Group PLC (LSE:RENE)
6.98p
0.00p
FTSE AIM All Share Pharmaceuticals & BiotechnologyMarket cap: £23.854m
Review a company's summary page in more detail and see the key fundamentals at a glance. Sign-up to Premium now to make your investment decisions.
Sign-up to Premium's Free 7 Day trial See an improved company summary
Summary
Research, development and commercial exploitation of stem cell technologies for therapeutic and non-therapeutic applications
| Financials - Interim (26/11/2009) | ||
|---|---|---|
| Turnover | £m | 0.01 |
| Pre-tax Profit | £m | -2.03 |
| EPS | p | -0.60 |
| DPS | p | 0.00 |
| Director | Board Role |
|---|---|
| Prof. Trevor Jones | Chairman |
| Michael Hunt | Chief Executive |
Products Brands & Subsidiaries
Products & Brands
There are no products for this company.
Subsidiaries
ReNeuron Ltd; ReNeuron Holdings Ltd
Broker Sentiment (2 brokers)
Strong SellStrong Buy
| Heading | Date |
|---|---|
| Issue of Ordinary Shares | 08/02/2010 |
| Regulatory update | 28/01/2010 |
| Regulatory update | 11/01/2010 |